A major source of op­ti­mism in the myeloma com­munity these days is the large num­ber of poten­tially very ef­fec­tive treat­ments under devel­op­ment for the dis­ease.

Increasing the num­ber of ef­fec­tive treat­ment op­tions for the dis­ease could lead to a sizable jump in sur­vival for both newly diag­nosed and re­lapsed mul­ti­ple myeloma patients.

There is, how­ever, a common theme among many of the promising inves­ti­ga­tional ther­a­pies for mul­ti­ple myeloma that could limit their ability to make as large an im­pact on …

Statistics compiled by The Myeloma Beacon show there is sub­stan­tial variation across U.S. cancer centers in the num­ber of au­tol­o­gous (own) stem cell trans­plants the centers per­form each year for people with mul­ti­ple myeloma.

The five busiest U.S. centers in terms of au­tol­o­gous trans­plants for mul­ti­ple myeloma carried out an average of 236 such trans­plants per center in 2017, the latest year for which data are pub­licly avail­able. That is a pace equal to almost one trans­plant per weekday at …

One of the lessons I have learned over time is that models are really valuable for making sense of things in life.

Now, the sort of models I have in mind aren’t the kind you build with plastic pieces and glue, or the kind you see in fashion shows.

The models I’m talking about are simplified versions of the real world, with the simplifications specifically designed to highlight the most im­por­tant features of whatever it is that’s being modeled.

Given …

Results of a small Phase 2 trial conducted in Switzerland indicate that the HIV treat­ment nelfinavir, in com­bi­na­tion with Velcade and dexa­meth­a­sone, has promising activity in patients with ad­vanced, Velcade-resistant multiple myeloma.

All 34 patients in the Swiss trial had pre­vi­ously been treated with, and stopped responding to, Velcade. All study par­tic­i­pants also were pre­vi­ously treated with Revlimid (lena­lido­mide) and had a median of five over­all prior lines of treat­ment.

In this heavily pre­treated patient group, the com­bi­na­tion of nelfinavir, …

Results of a study conducted in Switzerland indicate that selective digestive decontamination, a controversial strategy designed to reduce the risk of in­fec­tions, may be effective in myeloma patients undergoing au­tol­o­gous (own) stem cell trans­plan­ta­tion.

The authors of the new study retro­spec­tive­ly reviewed data for over 200 myeloma patients who underwent an inpatient stem cell trans­plant at two hos­pi­tals in Zurich, Switzerland, be­tween 2009 and 2015. About half the patients underwent selective digestive decontamination (SDD) during their trans­plants, while the other …

As I lie here in a clinic bed, watching the nurse put on her gown and gloves to prepare my infusion of Kyprolis (car­filz­o­mib), I wonder how this all became "normal."

I remember the first time I felt like a medical patient on this journey. It was in March 2016 when I went in for the first of what would be three (so far) bone marrow biopsies. I distinctly remember how strange it felt to be shown into a treat­ment …

Back in April, I wrote about my adventures with the Health Insurance Portability and Accountability Act (HIPAA). I had run into a specious HIPAA barrier when the on­col­ogy practice I treat at initially refused to email me my laboratory results, saying HIPAA did not allow emails. Several readers shared comments about their own ex­peri­ences and a few expressed interest in the memo I presented to my oncologist addressing my HIPAA right.

Before I write and before you read another sentence …